References
- Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
- Pfreundschuh M, Schubert J, Ziepert M, . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
- Koenigsmann M, Knauf W, Herold M, . Fludarabine and bendamustine in refractory and relapsed indolent lymphoma—a multicenter phase I/II Trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004;45:1821–1827.
- Friedberg JW, Vose JM, Kelly JL, . The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807–2812.
- Fowler N, Kahl BS, Lee P, . Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011;29:3389–3395.
- Herold M, Schulze A, Niederwieser D, . Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006;132:105–112.
- Rummel M. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) Blood 2009;114(Suppl. 1): Abstract 405.
- Weidmann E, Neumann A, Fauth F, . Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011;22:1839–1844.
- Peyrade F, Jardin F, Thieblemont C, . Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
- Weidmann E, Kim SZ, Rost A, . Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1285–1289.
- Tucci A, Ferrari S, Bottelli C, . A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547–4553.
- Thieblemont C, Grossoeuvre A, Houot R, . Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008;19:774–779.
- Schmitt CJ, Dietrich S, Ho AD, . Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. Ann Hematol 2012;91:391–397.
- Heintel D, Skrabs C, Hauswirth A, . Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. Ann Hematol 2010;89:163–169.